Skip to main content
. Author manuscript; available in PMC: 2021 Mar 22.
Published in final edited form as: Oncogene. 2021 Feb 1;40(11):1927–1941. doi: 10.1038/s41388-020-01577-5

Table 1. A summary of the drugs that have been developed to target the MET/HGF signalling pathway and their use in clinical trials, with a focus on those which have reached Phase III (completed or ongoing).

Inhibitor name Phase III Ongoing-Completed
Anti-HGF monoclonal antibodies Rilotumumab/ AMG-102 NCT02154490
Ficlatuzumab/ AV-299 / SCH 900105 Not yet conducted – trials completed and ongoing at Phase 2
HuL2G7 / TAK701 Not yet conducted – trial completed at Phase 1, none ongoing
YYB-101 Not yet conducted – trials completed at Phase 1 and ongoing at Phase 2
MET antagonists Onartuzumab / RO5490258 / PRO-142966 NCT02488330, NCT01662869, NCT01887886, NCT02031744
SAIT301 Not yet conducted – trial completed at Phase 1, none ongoing
Emibetuzumab/ LY2875358 / LA480 Not yet conducted – trials completed and ongoing at Phase 2
Amivantamab / JNJ-61186372 / JNJ-372 NCT04487080
ABT-700 / h224G11 Not yet conducted – trials completed at Phase 1 and ongoing at Phase 2
MET kinase inhibitors Tivantinib / ARQ 197 NCT02029157, NCT01755767, NCT01244191
Savolitinib/ AZD6094 / HMPL-504 / HMP-504 / Volitinib NCT03091192
Tepotinib / MSC2156119J/ EMD1214063 Not yet conducted – trials completed at Phase 1 and ongoing at Phase 2
Glesatinib/ MGCD265 Not yet conducted – trials completed and ongoing at Phase 2
Capmatinib/ INC280 NCT04427072, NCT03784014
PHA665752 Not yet conducted – no trials completed at any Phase
SU11274 Not yet conducted – no trials completed at any Phase
Foretinib / GSK1363089/ XL880 Not yet conducted – trials completed and ongoing at Phase 2
Merestinib/ LY2801653 Not yet conducted – trials completed at Phase 1 and ongoing at Phase 2
MK8033 Not yet conducted – trial completed at Phase 1, none ongoing
Multi-kinase kinase inhibitors Crizotinib / PF-02341066 Targets: MET, ALK, ROS, RON NCT02838420, NCT02075840, NCT01639001, NCT00932893, NCT01154140, NCT04009317, NCT03052608, NCT02737501, NCT02767804, NCT02201992, NCT03194893, NCT03126916, NCT03596866, NCT03874273
Cabozantinib / XL184, BMS907351 Targets: MET, VEGFR2, KIT, RET, AXL, FLT3 NCT01908426, NCT01605227, NCT01865747, NCT00704730, NCT03690388, NCT04338269, NCT03755791, NCT03937219, NCT03375320, NCT04446117, NCT03793166, NCT03729245, NCT03141177, NCT04211337
Amuvatinib / MP470 Targets: MET, c-Kit, PDGFRα, Flt3, c-Ret Not yet conducted – trial completed at Phase 2, none ongoing